PA007527.r1: In Vivo Grade Recombinant Anti-mouse VEGFR-2 Monoclonal Antibody (Clone: DC101), Rat IgG1 Kappa
The in vivo grade recombinant anti-mouse VEGFR-2 rat IgG1 monoclonal antibody (clone of DC101) was produced in mammalian cells.
Applications: Western blot, immunoprecipitation (IP), Flow Cytometry (FC), and various in vitro and in vivo functional assays.BP005736: Biotinylated Human VEGF R1/FLT-1 Protein with the C-His-Avi Tag
Source: The recombinant Biotinylated Human VEGF R1/FLT-1 Protein, (amino acids Ser27-Asn756) fused with a His-Avi tag at the C-terminus, was produced in HEK 293 cells.
Activity: Immobilized recombinant Human VEGF165 protein with the C-His-Avi tag at 1 ug/ml (100 ul/well) on the plate. Dose response curve for the recombinant Biotinylated Human VEGFR1 protein with the C-His tag with the EC50 of 46.4 ng/ml determined by ELISA (QC Test).
Purity: >95% by SEC-HPLC and SDS-PAGE under reducing conditions.
Endotoxin Level: Less than 1 EU per ug of protein as determined by LAL method.BP000988-PKA-234: Recombinant Human VEGFR1 D3
Source: Insect Cells-derived.
The activity of FLT1D1-3 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors, and in Far-Western and cross-linking experiments with iodinated VEGF.
Purity > 90%, by RP-HPLC and SDS-PAGE.BP000988-PKA-338: Recombinant Human VEGFR1 D3, His Tag
Source: Insect Cells-derived.
Purity > 95%, by RP-HPLC and SDS-PAGE.BP000989-PKA-235: Recombinant Human VEGFR1 D4
Source: Insect Cells-derived.
The activity of FLT1D1-4 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces, and in Far-Western and cross-linking experiments with iodinated VEGF.
Purity > 90%, by RP-HPLC and SDS-PAGE.BP000990-PKA-239: Recombinant Human VEGFR1 D5
Source: Insect Cells-derived.
The activity of FLT1 D5 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces. The ED50 for this effect is typically 10 ng/ml, corresponding to a specific activity of 100,000IU/mg.
Purity > 90%, by RP-HPLC and SDS-PAGE.BP000991-PKA-241: Recombinant Human VEGFR1 D17
Source: Insect Cells-derived.
The activity of FLT1/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for this effect is typically 10-30 ng/ml, corresponding to a specific activity of 33,333.33-100,000 units/mg.
Purity > 95%, by SDS-PAGE.BP000992-PKA-240: Recombinant Human VEGFR1
Source: Insect Cells-derived.
The activity of FLT1 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surface receptors. The ED50 for this effect is typically 10 ng/ml, corresponding to a specific activity of 100,000IU/mg.
Purity > 90%, by RP-HPLC and SDS-PAGE.BP000992-PKA-354: Recombinant Human VEGFR1, His Tag
Source: E. coli-derived.
Purity > 95%, by SDS-PAGE.APIM050161: GSK-1070916 (NMI-900)
CAS No.: 942918-07-2.
Purity: >99.5% (HPLC at 214 and 254 nm).
QC: HPLC-MS, 1HNMR, and Quatitative Elemental Analysis.
Solubility: In DMSO.